



26 January 2023
EMA/CHMP/26443/2023
Committee for Medicinal Products for Human Use (CHMP)

Summary of opinion¹ (post authorisation)

Trulicity

dulaglutide

On 26 January 2023, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending a change to the terms of the marketing authorisation for the medicinal product Trulicity. The marketing authorisation holder for this medicinal product is Eli Lilly Nederland B.V.

The CHMP adopted an extension to the existing indication to include children from 10 years of age. For information, the full indication will be as follows:²

Type 2 Diabetes Mellitus

Trulicity is indicated for the treatment of ~~adults~~ **patients 10 years and above** with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise

- as monotherapy when metformin is considered inappropriate due to intolerance or contraindications
- in addition to other medicinal products for the treatment of diabetes.

For study results with respect to combinations, effects on glycaemic control and cardiovascular events, and the populations studied, see sections 4.4, 4.5 and 5.1.

Detailed recommendations for the use of this product will be described in the updated summary of product characteristics (SmPC), which will be published in the revised European public assessment report (EPAR), and will be available in all official European Union languages after a decision on this change to the marketing authorisation has been granted by the European Commission.

¹ Summaries of positive opinion are published without prejudice to the Commission decision, which will normally be issued 67 days from adoption of the opinion

² New text in **bold**, removed text as strikethrough

